Scarica l'app Stockscreener
326.14
1.26%
-4.17
Dopo l'orario di chiusura:
326.14
Precedente Chiudi:
$330.31
Aprire:
$324.92
Volume 24 ore:
1.07M
Relative Volume:
0.79
Capitalizzazione di mercato:
$47.01B
Reddito:
$2.50B
Utile/perdita netta:
$-226.32M
Rapporto P/E:
-198.72
EPS:
-1.6412
Flusso di cassa netto:
$71.51M
1 W Prestazione:
-0.47%
1M Prestazione:
+2.45%
6M Prestazione:
+63.93%
1 anno Prestazione:
+92.08%
Intervallo 1D:
$320.65
$331.19
Intervallo di 1 settimana:
$320.65
$331.88
Portata 52W:
$157.43
$343.18
Natera Inc Stock (NTRA) Company Profile
Nome
Natera Inc
Settore
Industria
Telefono
650-249-9090
Indirizzo
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IQV, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
326.14 | 47.61B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
603.18 | 223.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
200.53 | 144.01B | 24.78B | 3.68B | 5.29B | 5.1743 |
IQV
Iqvia Holdings Inc
|
257.30 | 42.30B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
143.12 | 40.81B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-14 | Iniziato | William Blair | Outperform |
| 2026-01-07 | Iniziato | Citigroup | Buy |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-10-27 | Aggiornamento | BNP Paribas Exane | Underperform → Neutral |
| 2025-09-22 | Ripresa | Wells Fargo | Equal Weight |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-08 | Ripresa | Craig Hallum | Buy |
| 2024-02-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-11-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Iniziato | Bernstein | Mkt Perform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Iniziato | Stephens | Overweight |
| 2022-03-08 | Iniziato | Goldman | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-09-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-09-17 | Iniziato | SVB Leerink | Outperform |
| 2020-06-10 | Ripresa | Piper Sandler | Overweight |
| 2020-05-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Iniziato | JP Morgan | Neutral |
| 2018-07-05 | Reiterato | Piper Jaffray | Overweight |
| 2017-08-07 | Reiterato | Morgan Stanley | Overweight |
| 2016-11-10 | Reiterato | The Benchmark Company | Buy |
| 2016-05-23 | Reiterato | The Benchmark Company | Buy |
| 2016-05-11 | Reiterato | The Benchmark Company | Buy |
| 2016-04-19 | Iniziato | The Benchmark Company | Buy |
| 2015-09-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2015-08-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Iniziato | Robert W. Baird | Outperform |
| 2015-07-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Iniziato | Piper Jaffray | Overweight |
| 2015-07-27 | Iniziato | Wedbush | Neutral |
Mostra tutto
Natera Inc Borsa (NTRA) Ultime notizie
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - simplywall.st
NTRA Maintains Buy Rating by UBS -- Price Target Raised to $435 - GuruFocus
3 Reasons Investors Love Natera (NTRA) - Yahoo! Finance Canada
UBS Adjusts Price Target on Natera to $435 From $290, Keeps Buy Rating - Moomoo
Jim Cramer Calls Natera (NTRA) “a Promising Story” - Yahoo Finance
Net current asset value per share of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA - TradingView
Fed. Circ. Urged To Overturn Natera's Cancer Test Patent Win - Law360
Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia) - The Motley Fool
NTRA Initiated Coverage by Rothschild & Co -- Price Target Set a - GuruFocus
Can Natera (NTRA) Justify Its Valuation As Signatera Lymphoma Data Lifts Sentiment? - simplywall.st
Rothschild Redburn initiates Natera stock with buy on MRD leadership By Investing.com - Investing.com Nigeria
Rothschild Redburn initiates Natera stock with buy on MRD leadership - Investing.com
Debt to assets ratio of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAD - TradingView
Net debt of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - tradingview.com
Natera, Inc. (NTRA) Stock Analysis: A $47.31 Billion Healthcare Innovator with Strong Buy Ratings - DirectorsTalk Interviews
Net income before discontinued operations of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAD - TradingView
Diluted earnings per share (diluted EPS) of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - TradingView
Gross profit of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA - TradingView
NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) Revenue Breakdown – BCBA:NTRA.CI - TradingView
Natera Inc Cert Deposito Arg Repr 0.019607 Sh Revenue Breakdown – BCBA:NTRA - TradingView
Guggenheim maintains Buy on Natera, raises target to $290 - scanx.trade
Net income before discontinued operations of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAC - TradingView
The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership - simplywall.st
Natera CEO Steven Chapman sells $545k in NTRA shares By Investing.com - Investing.com South Africa
Natera president Solomon Moshkevich sells over $5.9m in shares By Investing.com - Investing.com South Africa
Here’s How Much You Would Have Made Owning Natera Stock In The Last 10 Years - Benzinga
Natera stock trades near 52-week high as guidance and regulatory wins support growth - ad-hoc-news.de
Natera Inc (NTRA) CEO and President Steven Chapman Sells 1,698 S - GuruFocus
Natera president Solomon Moshkevich sells over $5.9m in shares - Investing.com
Natera CEO Steven Chapman sells $545k in NTRA shares - Investing.com
Natera (NASDAQ: NTRA) exec sells shares for taxes and under pre-set plan - Stock Titan
Natera Unlocks Broader Signatera Adoption With FDA, PMDA And NCCN Milestones! - Smartkarma
Natera: $8.25M Prenatal Test Class Action Settlement Approved - Wansom AI
I would put Natera on my watch list and not chase the stock here, says Jim Cramer - CNBC
After recent stock sales, Natera (NASDAQ: NTRA) exec files notice to sell more shares - Stock Titan
Planned stock sale by Natera (NTRA) holder follows 41,124-share trade - Stock Titan
Natera (NASDAQ: NTRA) executive plans nearly $1M share sale after $2M in recent trades - Stock Titan
NTRA Looks 47.2% Overvalued on GF Value™ - GuruFocus
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma - Stock Titan
Natera teams with Angiex on cancer drug trial monitoring - Fierce Biotech
Pretax income of Natera, Inc. – LSX:A14VPJ - TradingView
Natera, Inc. (NTRA) Stock Analysis: A Healthcare Powerhouse with a 3.21% Upside Potential - DirectorsTalk Interviews
Natera Stock (NTRA) Opinions on Recent Price Surge - moomoo.com
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run? - The Motley Fool
Natera president John Fesko sells $2.1m in company stock By Investing.com - Investing.com Nigeria
Natera (NASDAQ: NTRA) exec gets 20K RSUs, sells shares for taxes - Stock Titan
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera - Eastern Progress
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer - finance.yahoo.com
Natera president John Fesko sells $2.1m in company stock - Investing.com
Natera (NTRA) Q1 2025 Earnings: Results, Market Reaction & History - 24/7 Wall St.
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™ - Yahoo Finance
Natera Inc Azioni (NTRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.12%
1.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):